The Myocarditis Treatment Trial: Design, methods and patient enrolment

E. A. Hahn, V. L. Hartz, T. E. Moon, J. B. O'Connell, A. Herskowitz, B. M. McManus, J. W. Mason*

*Corresponding author for this work

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The Myocarditis Treatment Trial was a multicentre clinical trial conducted to determine the efficacy of immunosuppressive therapy for treatment of biopsy-documented biopsy-documented myocarditis, and to improve understanding of the immunological mechanisms in the development of myocarditis. Thirty-one centres screened 2305 patients with unexplained heart failure, and 2233 patients underwent an endomyocardial biopsy which provided adequate tissue for diagnosis. Those with a positive biopsy and a left ventricular ejection fraction (LVEF) less than 45% were randomly assigned to receive immunosuppressive therapy plus conventional drug therapy for congestive heart failure (66 patients) or conventional therapy only (45 patients) for 24 weeks. For 28 additional weeks all patients received conventional therapy only. In addition to diagnostic and clinical data, serum and myocardial tissue for immunological marker analysis and histopathologic evaluation were collected at baseline and at 12, 28 and 52 weeks after randomization. The primary analysis of efficacy was designed as a comparison of the mean increase in LVEF at week 28 between treatment limbs. Secondary objectives were to evaluate survival differences, and changes in the histopathology of the disease and immunological markers. Randomized patients were relatively young (mean age, 42.0 years ± 13.8 standard deviation (sd)) and entered the Trial with a mean LVEF percent of 24.3 ± 10.1 sd) and mean exercise treadmill duration of 94 (± 5.3 sd) minutes. The incidence of biopsy-documented myocarditis was low (9.6%). The analyses of outcome and immunological data are reported elsewhere.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalEuropean Heart Journal
Volume16
Issue numberSUPPL. O
StatePublished - Jan 1 1995

Fingerprint

Myocarditis
Biopsy
Stroke Volume
Immunosuppressive Agents
Therapeutics
Heart Failure
Immune System Diseases
Random Allocation
Multicenter Studies
Extremities
Clinical Trials
Exercise
Drug Therapy
Survival
Incidence
Serum

Keywords

  • Azathioprine
  • Cyclosporine
  • Endomyocardial biopsy
  • Idiopathic dilated cardiomyopathy
  • Immunosuppressive therapy
  • Lymphocytic myocarditis
  • Prednisone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hahn, E. A., Hartz, V. L., Moon, T. E., O'Connell, J. B., Herskowitz, A., McManus, B. M., & Mason, J. W. (1995). The Myocarditis Treatment Trial: Design, methods and patient enrolment. European Heart Journal, 16(SUPPL. O), 162-167.
Hahn, E. A. ; Hartz, V. L. ; Moon, T. E. ; O'Connell, J. B. ; Herskowitz, A. ; McManus, B. M. ; Mason, J. W. / The Myocarditis Treatment Trial : Design, methods and patient enrolment. In: European Heart Journal. 1995 ; Vol. 16, No. SUPPL. O. pp. 162-167.
@article{90555dc50fdd4fb08ff84b04a645ae2e,
title = "The Myocarditis Treatment Trial: Design, methods and patient enrolment",
abstract = "The Myocarditis Treatment Trial was a multicentre clinical trial conducted to determine the efficacy of immunosuppressive therapy for treatment of biopsy-documented biopsy-documented myocarditis, and to improve understanding of the immunological mechanisms in the development of myocarditis. Thirty-one centres screened 2305 patients with unexplained heart failure, and 2233 patients underwent an endomyocardial biopsy which provided adequate tissue for diagnosis. Those with a positive biopsy and a left ventricular ejection fraction (LVEF) less than 45{\%} were randomly assigned to receive immunosuppressive therapy plus conventional drug therapy for congestive heart failure (66 patients) or conventional therapy only (45 patients) for 24 weeks. For 28 additional weeks all patients received conventional therapy only. In addition to diagnostic and clinical data, serum and myocardial tissue for immunological marker analysis and histopathologic evaluation were collected at baseline and at 12, 28 and 52 weeks after randomization. The primary analysis of efficacy was designed as a comparison of the mean increase in LVEF at week 28 between treatment limbs. Secondary objectives were to evaluate survival differences, and changes in the histopathology of the disease and immunological markers. Randomized patients were relatively young (mean age, 42.0 years ± 13.8 standard deviation (sd)) and entered the Trial with a mean LVEF percent of 24.3 ± 10.1 sd) and mean exercise treadmill duration of 94 (± 5.3 sd) minutes. The incidence of biopsy-documented myocarditis was low (9.6{\%}). The analyses of outcome and immunological data are reported elsewhere.",
keywords = "Azathioprine, Cyclosporine, Endomyocardial biopsy, Idiopathic dilated cardiomyopathy, Immunosuppressive therapy, Lymphocytic myocarditis, Prednisone",
author = "Hahn, {E. A.} and Hartz, {V. L.} and Moon, {T. E.} and O'Connell, {J. B.} and A. Herskowitz and McManus, {B. M.} and Mason, {J. W.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "16",
pages = "162--167",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. O",

}

Hahn, EA, Hartz, VL, Moon, TE, O'Connell, JB, Herskowitz, A, McManus, BM & Mason, JW 1995, 'The Myocarditis Treatment Trial: Design, methods and patient enrolment', European Heart Journal, vol. 16, no. SUPPL. O, pp. 162-167.

The Myocarditis Treatment Trial : Design, methods and patient enrolment. / Hahn, E. A.; Hartz, V. L.; Moon, T. E.; O'Connell, J. B.; Herskowitz, A.; McManus, B. M.; Mason, J. W.

In: European Heart Journal, Vol. 16, No. SUPPL. O, 01.01.1995, p. 162-167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Myocarditis Treatment Trial

T2 - Design, methods and patient enrolment

AU - Hahn, E. A.

AU - Hartz, V. L.

AU - Moon, T. E.

AU - O'Connell, J. B.

AU - Herskowitz, A.

AU - McManus, B. M.

AU - Mason, J. W.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The Myocarditis Treatment Trial was a multicentre clinical trial conducted to determine the efficacy of immunosuppressive therapy for treatment of biopsy-documented biopsy-documented myocarditis, and to improve understanding of the immunological mechanisms in the development of myocarditis. Thirty-one centres screened 2305 patients with unexplained heart failure, and 2233 patients underwent an endomyocardial biopsy which provided adequate tissue for diagnosis. Those with a positive biopsy and a left ventricular ejection fraction (LVEF) less than 45% were randomly assigned to receive immunosuppressive therapy plus conventional drug therapy for congestive heart failure (66 patients) or conventional therapy only (45 patients) for 24 weeks. For 28 additional weeks all patients received conventional therapy only. In addition to diagnostic and clinical data, serum and myocardial tissue for immunological marker analysis and histopathologic evaluation were collected at baseline and at 12, 28 and 52 weeks after randomization. The primary analysis of efficacy was designed as a comparison of the mean increase in LVEF at week 28 between treatment limbs. Secondary objectives were to evaluate survival differences, and changes in the histopathology of the disease and immunological markers. Randomized patients were relatively young (mean age, 42.0 years ± 13.8 standard deviation (sd)) and entered the Trial with a mean LVEF percent of 24.3 ± 10.1 sd) and mean exercise treadmill duration of 94 (± 5.3 sd) minutes. The incidence of biopsy-documented myocarditis was low (9.6%). The analyses of outcome and immunological data are reported elsewhere.

AB - The Myocarditis Treatment Trial was a multicentre clinical trial conducted to determine the efficacy of immunosuppressive therapy for treatment of biopsy-documented biopsy-documented myocarditis, and to improve understanding of the immunological mechanisms in the development of myocarditis. Thirty-one centres screened 2305 patients with unexplained heart failure, and 2233 patients underwent an endomyocardial biopsy which provided adequate tissue for diagnosis. Those with a positive biopsy and a left ventricular ejection fraction (LVEF) less than 45% were randomly assigned to receive immunosuppressive therapy plus conventional drug therapy for congestive heart failure (66 patients) or conventional therapy only (45 patients) for 24 weeks. For 28 additional weeks all patients received conventional therapy only. In addition to diagnostic and clinical data, serum and myocardial tissue for immunological marker analysis and histopathologic evaluation were collected at baseline and at 12, 28 and 52 weeks after randomization. The primary analysis of efficacy was designed as a comparison of the mean increase in LVEF at week 28 between treatment limbs. Secondary objectives were to evaluate survival differences, and changes in the histopathology of the disease and immunological markers. Randomized patients were relatively young (mean age, 42.0 years ± 13.8 standard deviation (sd)) and entered the Trial with a mean LVEF percent of 24.3 ± 10.1 sd) and mean exercise treadmill duration of 94 (± 5.3 sd) minutes. The incidence of biopsy-documented myocarditis was low (9.6%). The analyses of outcome and immunological data are reported elsewhere.

KW - Azathioprine

KW - Cyclosporine

KW - Endomyocardial biopsy

KW - Idiopathic dilated cardiomyopathy

KW - Immunosuppressive therapy

KW - Lymphocytic myocarditis

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=0029555395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029555395&partnerID=8YFLogxK

M3 - Article

C2 - 8682088

AN - SCOPUS:0029555395

VL - 16

SP - 162

EP - 167

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. O

ER -

Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM et al. The Myocarditis Treatment Trial: Design, methods and patient enrolment. European Heart Journal. 1995 Jan 1;16(SUPPL. O):162-167.